The Russian Expert Council on the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma. Event review

封面

如何引用文章

全文:

详细

The meeting of the expert council concerning the application of new highly selective inhibitor of Bruton’s tyrosine kinase zanubrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma was held in Moscow on April 21, 2021. The leading Russian experts in the field of oncohematology took part in the meeting.

作者简介

Kamil Kaplanov

Botkin City Clinical Hospital

编辑信件的主要联系方式.
Email: kamilos@mail.ru
ORCID iD: 0000-0001-6574-0518

Cand. Sci. (Med.)

俄罗斯联邦, Moscow

参考

  1. Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903-10. doi: 10.1182/blood-2017-04-779736; PMID: 28819011
  2. Hill HA, Qi X, Jain P, et al. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2020;4(13):2927-38. doi: 10.1182/bloodadvances.2019001350; PMID: 32598477; PMCID: PMC7362354
  3. Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 2019;94(6):710-25. doi: 10.1002/ajh.25487; PMID: 30963600
  4. Ferrero S, Rossi D, Rinaldi A, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020;105(6):1604-12. doi: 10.3324/haematol.2018.214056; PMID: 31537689; PMCID: PMC7271566
  5. McCulloch R, Visco C, Eyre TA, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 2020;189(4):684-8. doi: 10.1111/bjh.16416; PMID: 32011729
  6. Rule S, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia. 2018;32(8):1799-803. doi: 10.1038/s41375-018-0023-2; PMID: 29572505; PMCID: PMC6087720
  7. Sharman J, Kabadi SM, Clark J, Andorsky D. Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study. Br J Haematol. 2021;192(4):737-46. doi: 10.1111/bjh.16922; PMID: 33095453
  8. Dimopoulos M, Sanz RG, Lee HP, et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv. 2020;4(23):6009-18. doi: 10.1182/bloodadvances.2020003010; PMID: 33284944; PMCID: PMC7724905
  9. Hillmen P, Brown JR, Eichhorst BF, et al. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncol. 2020;16(10):517-23. doi: 10.2217/fon-2019-0844; PMID: 32207333
  10. Tam CS, Opat S, D’Sa S, Jurczak W, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038-50. doi: 10.1182/blood.2020006844; PMID: 32731259; PMCID: PMC7596850
  11. Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851-9. doi: 10.1182/blood.2019001160; PMID: 31340982; PMCID: PMC6742923
  12. Song Y, Zhou K, Zou D, et al. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton’s Tyrosine Kinase. Clin Cancer Res. 2020;26(16):4216-24. doi: 10.1158/1078-0432.CCR-19-3703; PMID: 32461234
  13. Byrd JC, Wierda WG, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020;135(15):1204-13. doi: 10.1182/blood.2018884940; PMID: 31876911; PMCID: PMC7146022
  14. Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104(5):e211-4. doi: 10.3324/haematol.2018.205229; PMID: 30442728; PMCID: PMC6518912
  15. Owen C, Berinstein NL, Christofides A, Sehn LH. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol. 2019;26(2):e233-40. doi: 10.3747/co.26.4345; PMID: 31043832; PMCID: PMC6476444
  16. Tang CPS, McMullen J, Tam C. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leuk Lymphoma. 2018;59(7):1554-64. doi: 10.1080/10428194.2017.1375110; PMID: 28901789
  17. Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134(22):1919-28. doi: 10.1182/blood.2019000840; PMID: 31582362; PMCID: PMC6887116
  18. Ratain MJ, Moslehi JJ, Lichter AS. Ibrutinib’s Cardiotoxicity-An Opportunity for Postmarketing Regulation. JAMA Oncol. 2021;7(2):177-8. doi: 10.1001/jamaoncol.2020.5742; PMID: 33237281
  19. Shafaattalab S, Lin E, Christidi E, et al. Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes. Stem Cell Reports. 2019;12(5):996-1006. doi: 10.1016/j.stemcr.2019.03.011; PMID: 31031187; PMCID: PMC6524928

版权所有 © Consilium Medicum, 2021

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##